Cancer Services, 71459Kingston Health Sciences Centre, Kingston, Ontario, Canada.
Safety Initiatives Systemic Treatment Program, Ontario Health, Cancer Care Ontario, Toronto, Ontario, Canada.
J Oncol Pharm Pract. 2023 Mar;29(2):401-412. doi: 10.1177/10781552221135121. Epub 2022 Nov 13.
This evidence-based practice guideline was developed to update and address new issues in the handling of hazardous drugs including being compliant with NAPRA (National Association of Pharmacy Regulatory Authorities) and USP 800 (United States Pharmacopeia) standards, the use of personal protective equipment and treatment in diverse settings including in the home setting. This guideline was developed from an adaptation and endorsement of existing guidelines and from three systematic reviews. Prior to publication, this guideline underwent a series of peer, patient, methodological and external reviews to gather feedback. All comments were addressed and the guideline was amended when required. This guideline applies to and is intended for all health care workers who may come into contact with hazardous drugs at any point in the medication circuit. The recommendations represent a reasonable and practical set of procedures that the intended users of this guideline should implement to minimize the opportunity for accidental exposure. These recommendations are not limited to just the point of care, but cover the entire chain of handling of cytotoxics from the time they enter the institution until they leave in the patient or as waste. Decreasing the likelihood of accidental exposure to cytotoxic agents within the medication circuit is the main objective of this evidenced-based guideline. The recommendations differ slightly from previous guidelines due to new evidence.
本循证实践指南旨在更新和解决处理危害药物方面的新问题,包括符合 NAPRA(国家药剂监管机构协会)和 USP 800(美国药典)标准、使用个人防护设备以及在包括家庭环境在内的各种环境中的治疗。该指南是通过改编和认可现有指南以及三项系统评价制定的。在发布之前,该指南经历了一系列同行、患者、方法学和外部审查,以收集反馈。所有意见都得到了处理,必要时对指南进行了修订。本指南适用于并针对所有可能在药物治疗过程中的任何阶段接触危害药物的医疗保健工作者。这些建议代表了一套合理且实用的程序,本指南的预期使用者应实施这些程序,以最大程度地减少意外接触的机会。这些建议不仅限于护理点,还涵盖了从药物进入机构到离开患者或作为废物的整个细胞毒药物处理链。降低药物治疗过程中细胞毒药物意外接触的可能性是本循证指南的主要目标。由于新证据,建议与之前的指南略有不同。